Unknown

Dataset Information

0

Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections.

ABSTRACT: We determined and compared the humoral immune response in severe, hospitalized and mild, non-hospitalized COVID-19 patients. Severe patients (n=38) develop a robust antibody response to SARS-CoV-2, including IgG and IgA antibodies. The geometric mean 50% virus neutralization titer is 1:240. SARS-CoV-2 infected hospital personnel (n=24), who developed mild symptoms necessitating leave of absence, self-isolation, but not hospitalization, 75 % develop antibodies, but with low/absent virus neutralization (60% < 1:20). While severe COVID-19 patients develop a strong antibody response, mild SARS-CoV-2 infections induce a modest antibody response. Long term monitoring will show whether these responses predict protection against future infections.

SUBMITTER: Rijkers G 

PROVIDER: S-EPMC7454692 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections.

Rijkers Ger G   Murk Jean-Luc JL   Wintermans Bas B   van Looy Bieke B   van den Berge Marcel M   Veenemans Jacobien J   Stohr Joep J   Reusken Chantal C   van der Pol Pieter P   Reimerink Johan J  

The Journal of infectious diseases 20200901 8

We determined and compared the humoral immune response in patients with severe (hospitalized) and mild (nonhospitalized) coronavirus disease 2019 (COVID-19). Patients with severe disease (n = 38) develop a robust antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including immunoglobulin G and immunoglobulin A antibodies. The geometric mean 50% virus neutralization titer is 1:240. SARS-CoV-2 infection was found in hospital personnel (n = 24), who developed mild sy  ...[more]

Similar Datasets

Unknown Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections.
| S-EPMC6759241 | biostudies-literature
Unknown Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.
| S-EPMC7323511 | biostudies-literature
Unknown Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2.
| S-EPMC7454076 | biostudies-literature
Unknown Molecular epidemiology of severe acute respiratory syndrome-associated coronavirus infections in Taiwan.
| S-EPMC7199491 | biostudies-literature
Unknown Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
| S-EPMC7468315 | biostudies-literature
Unknown Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019.
| S-EPMC7890673 | biostudies-literature
Unknown Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.
| S-EPMC4018502 | biostudies-literature
Unknown Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection.
| S-EPMC5450662 | biostudies-literature
Unknown Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019.
| S-EPMC8083268 | biostudies-literature
Unknown Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.
| S-EPMC8099238 | biostudies-literature